AI Issuer Brief
ClaudeLoading cached brief…
Peers
No peer list available for VRDN.
Price change · trailing returns
Live · FMP| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.97% | -2.11% | +30.71% | -40.03% | -44.87% | -43.38% | +26.13% | -26.06% | +0.97% | -86.73% | -99.14% |
Aftermarket
Live · FMPLast trade
$17.10
1 sh
Bid
$15.70
2 sh
Ask
$18.93
90 sh
Spread
$3.230
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Analyst PT consensus: $38.13 (+116.40%)
Total assets
—
Total debt
—
Cash & equiv
—
Operating CF
—
Free cash flow
—
Buybacks
—
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Millionbusinesswire.com·May 06, 2026
- Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stockbusinesswire.com·May 05, 2026
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
Fairmount Funds Management LLC director, 10 percent owner: | Buy | 1M | $20M | May 11, 2026 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|